4.4 Article

Valproic Acid Inhibits Glial Scar Formation after Ischemic Stroke

Journal

PHARMACOLOGY
Volume 107, Issue 5-6, Pages 263-280

Publisher

KARGER
DOI: 10.1159/000514951

Keywords

Astrocytes; Glial scar; Histone deacetylase; Hsp70; 1B; Ischemic stroke; Valproic acid; Oxygen; Glucose deprivation

Funding

  1. National Natural Science Foundation of China [82073841, 81874311, 81473211, 81171104]
  2. Jiangsu Key Laboratory of Neuropsychiatric Dis-eases [BM2013003]
  3. Jiangsu Key Laboratory of Preventive and Translational Medicine for Geriatric Diseases
  4. Academic Pro-gram Development of Jiangsu Higher Education Institutions (PAPD)

Ask authors/readers for more resources

This study found that valproic acid (VPA) has neuroprotective effects against ischemic stroke and inhibits glial scar formation by inhibiting histone deacetylase and inducing Hsp70.1B.
Introduction: Cerebral ischemia induces reactive proliferation of astrocytes (astrogliosis) and glial scar formation. As a physical and biochemical barrier, the glial scar not only hinders spontaneous axonal regeneration and neuronal repair but also deteriorates the neuroinflammation in the recovery phase of ischemic stroke. Objectives: Previous studies have shown the neuroprotective effects of the valproic acid (2-n-propylpentanoic acid, VPA) against ischemic stroke, but its effects on the ischemia-induced formation of astrogliosis and glial scar are still unknown. As targeting astrogliosis has become a therapeutic strategy for ischemic stroke, this study was designed to determine whether VPA can inhibit the ischemic stroke-induced glial scar formation and to explore its molecular mechanisms. Methods: Glial scar formation was induced by an ischemia-reperfusion (I/R) model in vivo and an oxygen and glucose deprivation (OGD)-reoxygenation (OGD/Re) model in vitro. Animals were treated with an intraperitoneal injection of VPA (250 mg/kg/day) for 28 days, and the ischemic stroke-related behaviors were assessed. Results: Four weeks of VPA treatment could markedly reduce the brain atrophy volume and improve the behavioral deficits in rats' I/R injury model. The results showed that VPA administrated upon reperfusion or 1 day post-reperfusion could also decrease the expression of the glial scar makers such as glial fibrillary acidic protein, neurocan, and phosphacan in the peri-infarct region after I/R. Consistent with the in vivo data, VPA treatment showed a protective effect against OGD/Re-induced astrocytic cell death in the in vitro model and also decreased the expression of GFAP, neurocan, and phosphacan. Further studies revealed that VPA significantly upregulated the expression of acetylated histone 3, acetylated histone 4, and heat-shock protein 70.1B in the OGD/Re-induced glial scar formation model. Conclusion: VPA produces neuroprotective effects and inhibits the glial scar formation during the recovery period of ischemic stroke via inhibition of histone deacetylase and induction of Hsp70.1B.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available